本帖最后由 老马 于 2012-1-13 21:20 编辑 4 m8 V5 ^0 m# m
' @: q+ M" u' u) C
爱必妥和阿瓦斯丁的比较5 ]/ y2 z0 A# L6 h$ Q
$ M6 l% l8 i' X% p1 C/ m9 x! Z
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/7 B( V" B/ H4 ^# g
- ]( j& ?/ F. n0 x
, _) Q* b t; \. @" lhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
; x9 P( q0 m) D==================================================
( }0 l: q6 U w; iOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
9 d/ k, Y( c5 \. r- P. sPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
1 p% z7 P) R& r, ZResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
8 y) Z8 T3 F7 E3 t
|